atherosclerosis News

Latest Articles

• Baylor College Researchers Identify Purine Synthesis as Biological Shield Against Artery Disease Progression

  Published: Apr 28, 2026

  Section: Medical News

  Scientists at Baylor College of Medicine have discovered a natural defense mechanism in blood vessels that slows the development of atherosclerosis by repairing DNA damage. The stu...

• Baylor Researchers Uncover Natural DNA Repair Mechanism That Shields Arteries From Advanced Atherosclerosis Development

  Published: Apr 28, 2026

  Section: Medical News

  A study led by Baylor College of Medicine has identified a self-protective metabolic response in endothelial cells that mitigates arterial damage caused by disturbed blood flow. Re...

• Clinical Trial Data Reveals Potent Triglyceride Lowering Drug Olezarsen Fails to Reduce Coronary Plaque Volume After One Year of Treatment

  Published: Mar 31, 2026

  Section: Health

  A sub-study presented at the American College of Cardiology’s Annual Scientific Session (ACC.26) found that while the drug olezarsen slashed triglyceride levels by 60%, it did not...

• Mass General Brigham Study Finds Intensive Cholesterol Treatment Cuts First-Time Heart Events by Thirty-One Percent in Diabetic Patients

  Published: Mar 30, 2026

  Section: Research

  A new analysis from the VESALIUS-CV trial presented at ACC.26 reveals that the PCSK9 inhibitor evolocumab significantly benefits high-risk diabetic patients before they develop kno...

• New Trial Results Prove PCSK9 Inhibitors Reduce Major Cardiovascular Events by Thirty-One Percent in High-Risk Diabetic Patients

  Published: Mar 30, 2026

  Section: Research

  A landmark subgroup analysis of the VESALIUS-CV trial presented at ACC.26 reveals that the cholesterol-lowering drug evolocumab provides significant protective benefits for diabeti...

• New Clinical Trial Reveals Cholesterol-Lowering Injection Reduces Major Heart Events by Thirty-One Percent in High-Risk Diabetic Patients

  Published: Mar 30, 2026

  Section: Medical News

  A landmark subgroup analysis of the VESALIUS-CV trial presented at ACC.26 shows that the PCSK9 inhibitor evolocumab significantly benefits diabetic patients even before the develop...